A group of researchers from the Hubert Curien Multidisciplinary Institute (IPHC) has begun an innovative research program on the interaction of cannabidiol (CBD), the non-psychoactive component of cannabis, and pancreatic cancer cells.
The professor in charge, Christian D Muller, has previously researched his therapeutic values. However, this is the first time he has done it with innovative methods.
Follow us on instagram: @mcnglobal
With the support of the European community for cannabis research for medicinal use, doctors in France carry out serious studies in clinics and hospitals with the only intention: to relieve the sick.
This case is about the study of the therapeutic action of CBD in enriched extracts and its action on cancer. In France, pancreatic cancer is one of the most aggressive and deadly today.
This research is both innovative since Professor Muller’s team uses a 3D cell culture procedure in the form of liquid pearls.
This method allows to obtain a more representative model of cancerous tumors, tumors and metastases. In this way the cancer cells are placed in polymer particles that form a kind of liquid pearls in a water resistant environment. Innovation goes through the absence of animals to perform this test.
Although the results have not yet been published, the results are quite promising.
Involved believe that this medicine can bring relief to patients
Professor Muller is part of the UFCM I Care association whose objectives are to group a group of professionals who help patients who want to improve their conditions with cannabis under the law and quality standards.
This group is made up of medical researchers and members of the scientific community who believe that the use of hemp and therapeutic cannabis can help relieve pain for both treatments and symptoms linked to these pathologies.
Professor Muller has experienced has seen relief with his own eyes, both for cancer-related side effects, and for his treatment. For example in fatigue pains nausea and loss of appetite.
“Medical cannabis is used successfully in people suffering from sclerosis and in autistic children. It has the advantage that it does not generate dependence contrary to opioids, ”he said in an interview.
France goes with everything
At the beginning of the month, we announced the news that the National Agency for the Safety of Medicines and Health Products (ANSM, French acronym) has launched a study plan on medical cannabis.
This is an evaluation of the relevance and weakness of the implementation of medical cannabis in France, as the Senate voted unanimously on May 28.